Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Unknown 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 15Leukemia 11Burkitt Lymphoma 10Lymphoma 4Leukemia, Biphenotypic, Acute 4Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Leukemia, Promyelocytic, Acute 2Down Syndrome 2Dendritic Cell Sarcoma, Interdigitating 2Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Immunoblastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Myelomonocytic, Juvenile 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1Leukemia, Lymphocytic, Chronic, B-Cell 1

Interventions

Cytarabine 11fludarabine phosphate 8Peripheral Blood Stem Cell Transplantation 7Etoposide 7Filgrastim 6Daunorubicin 6Vorinostat 5Specimen Handling 5Decitabine 5Cyclophosphamide 5Busulfan 5Biopsy 5Methotrexate 4Cyclosporine 4venetoclax 3sargramostim 3decitabine and cedazuridine drug combination 3Liposomes 3Injections 3Idarubicin 3CPX-351 3Azacitidine 3tipifarnib 2romidepsin 2pomalidomide 2laromustine 2fludarabine 2Vincristine 2Tretinoin 2Transplantation 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Myeloproliferative Disorders × Mercaptopurine × Clear all
NCT00047268 2013-09-17

Donor Stem Cell Transplant With or Without Chemotherapy in Treating Children With Primary Myelodysplastic Syndrome

National Cancer Institute (NCI)

Phase 3 Unknown
MyeloidOther hematologic neoplasm

Leukemia, Myeloproliferative Disorders, Leukemia, Myelomonocytic, Chronic, Leukemia, Myelomonocytic, Juvenile, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative

Data powered by HemOnc (CC BY 4.0) Colophon âš¡